Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12869753 | 1.00 | BLM (0.58) | BLMLMNACA1PTPN1ALDH1A1 | |
| SCHEMBL12869752 | 1.00 | BLM (0.58) | BLMLMNACA1PTPN1ALDH1A1 | |
| SCHEMBL1781111 | 0.95 | BLM (0.52) | BLMLMNACA1PTPN1ALDH1A1 | |
| SCHEMBL12153331 | 0.86 | CA1 (0.48) | BLMCA1ALDH1A1TDP1KISS1R | |
| SCHEMBL1784505 | 0.83 | BLM (0.44) | BLMCA1ALDH1A1TDP1KISS1R | |
| SCHEMBL12153332 | 0.83 | CA1 (0.46) | BLMCA1LTA4H | |
| SCHEMBL13410354 | 0.80 | GABRR1 (0.46) | BLMCA1ALDH1A1TDP1LTA4H | |
| SCHEMBL12410220 | 0.79 | — | — | |
| SCHEMBL7546267 | 0.79 | — | — | |
| SCHEMBL20489993 | 0.79 | BLM (0.58) | BLMLMNACA1PTPN1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469615-B2 | Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9290453-B2 | Quinolines and aza-quinolines as CRTH2 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-8632792-B2 | Cooling sensation agent composition and sensory stimulation agent composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2013-11-14 | — | — | US | disclosed |
| US-20130296300-A1 | QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110015397-A1 | Selective Aliphatic C-H Oxidation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015397-A1 | Selective Aliphatic C-H Oxidation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-01-20 | — | — | US | disclosed |
| US-7829342-B2 | composition including a complex of a metal, a tetradentate ligand, at least one ancillary ligand, and a counterion is used for selective sp3 C H bond oxidation; includes a N-heterocyclic-N,N'-bis(pyridyl)-ethane-1,2-diamine group or a N,N'-bis(heterocyclic)-N,N'-bis(pyridyl)-ethane-1,2-diamine group | THE BOARD OF TRUSTEES OF THE UNIVERSIY OF ILLINOIS (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829342-B2 | composition including a complex of a metal, a tetradentate ligand, at least one ancillary ligand, and a counterion is used for selective sp3 C H bond oxidation; includes a N-heterocyclic-N,N'-bis(pyridyl)-ethane-1,2-diamine group or a N,N'-bis(heterocyclic)-N,N'-bis(pyridyl)-ethane-1,2-diamine group | THE BOARD OF TRUSTEES OF THE UNIVERSIY OF ILLINOIS (US) | 2010-11-09 | — | — | US | disclosed |
| CN-101679176-A | Aldol condensation reaction and catalyst therefore | DSM IP ASSETS BV | 2010-03-24 | — | — | CN | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
| US-20090221083-A1 | Selective Aliphatic C-H Oxidation | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221083-A1 | Selective Aliphatic C-H Oxidation | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) | 2009-09-03 | — | — | US | disclosed |
| US-4021461-A | INSECTICIDES | ZOECON CORPORATION (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015397-A1 | Selective Aliphatic C-H Oxidation | AOC3, SOD3, AP3S1 | BLM 3998/4885LMNA 1882/4885CA1 1260/4885 |
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | HRH2, NPY2R, CNKSR1 | BLM 1408/4885LMNA 3865/4885CA1 4176/4885 |
| US-20090221083-A1 | Selective Aliphatic C-H Oxidation | AOC3, SOD3, AP3S1 | BLM 3998/4885LMNA 1882/4885CA1 1260/4885 |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TRPA1, HRH1, HRH2 | BLM 4418/4885LMNA 1708/4885CA1 3505/4885 |
| US-20130296300-A1 | QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS | HRH2, NPY2R, CNKSR1 | BLM 2058/4885LMNA 3568/4885CA1 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.